Ovid Therapeutics Inc.
OVID · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.02 | -0.07 | 0.05 |
| FCF Yield | -792.12% | -20.35% | -46.39% | -15.09% |
| EV / EBITDA | 1.40 | -1.99 | -1.25 | -5.09 |
| Quality | ||||
| ROIC | -21.42% | -7.12% | -16.72% | -12.72% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 1.06 | 1.02 | 1.00 | 1.08 |
| Growth | ||||
| Revenue 3-Year CAGR | 181.51% | 222.45% | 64.38% | -27.78% |
| Free Cash Flow Growth | -169.63% | 53.56% | -2.76% | 33.32% |
| Safety | ||||
| Net Debt / EBITDA | 1.53 | 3.12 | 0.54 | 1.07 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -3,590.91 | 0.00 | 0.00 |